- A + HIGH CONTRAST TURN ON TEXT TO SPEECH HOME ABOUT US PIPELINE TECHNOLOGY INVESTORS NEWS&MEDIA CONTACT & ACCESS Gene Therapy Against Blindness Created in 2013, GenSight Biologics (Euronext: SIGHT, FR0013183985) is a Phase III clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at several innovative ophthalmology companies. Our initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Press Releases 01 August 2017 GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of LHON Paris, France, August 1, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that enrollment in RESCUE, a Phase III clinical trial of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), has been successfully completed. READ THE FULL PRESS RELEASE 23 June 2017 GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe 14 June 2017 GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) 03 May 2017 GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer READ ALL PRESS RELEASES Main events 27 - 28 Sept. 2017 5th Annual Targeting Ocular Diseases, Boston (MA) Anne Douar, PhD, Project Director, is invited to give an oral presentation entitled " Optogenetic Therapy for Retinal Dystrophies " on September 27 at 5:30 PM. 10 Oct. 2017 Chardan Inaugural Gene Therapy Conference, NYC (US) Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer, are invited to present and will host meetings at the upcoming Chardan Gene Therapy Conference. 17 - 20 Oct. 2017 ESGCT, Berlin, Germany GenSight will present 5 abstracts: one oral presentation and 4 poster presentations concerning both its lead products GS010 to treat LHON and GS030 an optogenetics approach for RP. 09 Nov. 2017 Ophthalmology Innovation Summit @ AAO, New Orleans (LA) GenSight will attend the OIS on the occasion of the American Academy of Ophthalmology, November 11-14, 2017, in New Orleans (LA). OTHER EVENTS Discover our corporate video FRENCH (5'23") ENGLISH (5'23") HOME ABOUT US Company Scientific Founders Management Board Scientific advisory board Partners PIPELINE Leber Hereditary Optic Neuropathy (LHON) Retinitis Pigmentosa (RP) Geographic Atrophy in Dry-AMD Clinical trials TECHNOLOGY Gene Therapy Mitochondrial Targeting Sequence (MTS) Optogenetics INVESTORS Welcome ! Stock data Press releases News room Documentation Contact NEWS&MEDIA Press releases Events CONTACT & ACCESS ©2015-2017 Gensight Biologics Terms of Use Sitemap Gensight Biologics 74, rue du Faubourg Saint-Antoine 75012 Paris, FRANCE Phone: +33 1 76 21 72 20 infos@gensight-biologics.com